These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10640588)

  • 21. Integrin-targeted paclitaxel nanoliposomes for tumor therapy.
    Meng S; Su B; Li W; Ding Y; Tang L; Zhou W; Song Y; Caicun Z
    Med Oncol; 2011 Dec; 28(4):1180-7. PubMed ID: 20645030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel and its formulations.
    Singla AK; Garg A; Aggarwal D
    Int J Pharm; 2002 Mar; 235(1-2):179-92. PubMed ID: 11879753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel.
    Chen DB; Yang TZ; Lu WL; Zhang Q
    Chem Pharm Bull (Tokyo); 2001 Nov; 49(11):1444-7. PubMed ID: 11724235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
    Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X
    Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
    Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
    Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.
    Sharma US; Balasubramanian SV; Straubinger RM
    J Pharm Sci; 1995 Oct; 84(10):1223-30. PubMed ID: 8801338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative formulations of paclitaxel.
    Terwogt JM; Nuijen B; Huinink WW; Beijnen JH
    Cancer Treat Rev; 1997 Mar; 23(2):87-95. PubMed ID: 9225960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs.
    Sugahara S; Kajiki M; Kuriyama H; Kobayashi TR
    Biol Pharm Bull; 2002 May; 25(5):632-41. PubMed ID: 12033505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation.
    Bhatt P; Lalani R; Vhora I; Patil S; Amrutiya J; Misra A; Mashru R
    Int J Pharm; 2018 Jan; 536(1):95-107. PubMed ID: 29175440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and characterization of novel poly(ethylene glycol) paclitaxel derivatives.
    Arpicco S; Stella B; Schiavon O; Milla P; Zonari D; Cattel L
    Int J Pharm; 2013 Oct; 454(2):653-9. PubMed ID: 23701999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposils: An effective strategy for stabilizing Paclitaxel loaded liposomes by surface coating with silica.
    Ingle SG; Pai RV; Monpara JD; Vavia PR
    Eur J Pharm Sci; 2018 Sep; 122():51-63. PubMed ID: 29936087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
    Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
    Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
    Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
    J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma.
    Sharma D; Chelvi TP; Kaur J; Ralhan R
    Melanoma Res; 1998 Jun; 8(3):240-4. PubMed ID: 9664145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol).
    Lundberg BB
    J Pharm Pharmacol; 1997 Jan; 49(1):16-21. PubMed ID: 9120763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma.
    Gong C; Xie Y; Wu Q; Wang Y; Deng S; Xiong D; Liu L; Xiang M; Qian Z; Wei Y
    Nanoscale; 2012 Sep; 4(19):6004-17. PubMed ID: 22910790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
    Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model.
    Sharma A; Mayhew E; Straubinger RM
    Cancer Res; 1993 Dec; 53(24):5877-81. PubMed ID: 7903197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
    Sharma A; Straubinger RM; Ojima I; Bernacki RJ
    J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug.
    Stevens PJ; Sekido M; Lee RJ
    Pharm Res; 2004 Dec; 21(12):2153-7. PubMed ID: 15648245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.